α-Synuclein Strains and Their Relevance to Parkinson's Disease, Multiple System Atrophy, and Dementia with Lewy Bodies

被引:10
|
作者
Graves, Noah J.
Gambin, Yann
Sierecki, Emma [1 ]
机构
[1] Univ New South Wales, Fac Med, EMBL Australia Node Single Mol Sci, Sydney, NSW 2052, Australia
关键词
& alpha; -synuclein; amyloid fibrils; Parkinson's disease; dementia with Lewy bodies; multiple system atrophy; strain; ALPHA-SYNUCLEIN STRAINS; HUMAN BRAINS; TAU; PATHOGENESIS; FIBRILS; APPENDECTOMY; TRANSMISSION; DUPLICATION; AGGREGATION; INCLUSIONS;
D O I
10.3390/ijms241512134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Like many neurodegenerative diseases, Parkinson's disease (PD) is characterized by the formation of proteinaceous aggregates in brain cells. In PD, those proteinaceous aggregates are formed by the a-synuclein (aSyn) and are considered the trademark of this neurodegenerative disease. In addition to PD, aSyn pathological aggregation is also detected in atypical Parkinsonism, including Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), as well as neurodegeneration with brain iron accumulation, some cases of traumatic brain injuries, and variants of Alzheimer's disease. Collectively, these (and other) disorders are referred to as synucleinopathies, highlighting the relation between disease type and protein misfolding/aggregation. Despite these pathological relationships, however, synucleinopathies cover a wide range of pathologies, present with a multiplicity of symptoms, and arise from dysfunctions in different neuroanatomical regions and cell populations. Strikingly, aSyn deposition occurs in different types of cells, with oligodendrocytes being mainly affected in MSA, while aggregates are found in neurons in PD. If multiple factors contribute to the development of a pathology, especially in the cases of slow-developing neurodegenerative disorders, the common presence of aSyn aggregation, as both a marker and potential driver of disease, is puzzling. In this review, we will focus on comparing PD, DLB, and MSA, from symptomatology to molecular description, highlighting the role and contribution of aSyn aggregates in each disorder. We will particularly present recent evidence for the involvement of conformational strains of aSyn aggregates and discuss the reciprocal relationship between aSyn strains and the cellular milieu. Moreover, we will highlight the need for effective methodologies for the strainotyping of aggregates to ameliorate diagnosing capabilities and therapeutic treatments.
引用
收藏
页数:23
相关论文
共 50 条
  • [41] ALPHA-SYNUCLEIN AGGREGATION AND SYNAPTIC PATHOLOGY IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES
    Stefanis, Leonidas
    NEUROBIOLOGY OF AGING, 2016, 39 : S4 - S4
  • [42] Treatment of Dementia with Lewy Bodies and Parkinson's Disease Dementia
    Ballard, Clive
    Kahn, Zunera
    Corbett, Anne
    DRUGS & AGING, 2011, 28 (10) : 769 - 777
  • [43] Accumulation of NACP/α-synuclein in Lewy body disease and multiple system atrophy
    Shoji, M
    Harigaya, Y
    Sasaki, A
    Uéda, K
    Ishiguro, K
    Matsubara, E
    Watanabe, M
    Ikeda, M
    Kanai, M
    Tomidokoro, Y
    Shizuka, M
    Amari, M
    Kosaka, K
    Nakazato, Y
    Okamoto, K
    Hirai, S
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (05) : 605 - 608
  • [44] Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies
    Parnetti, Lucilla
    Tiraboschi, Pietro
    Lanari, Alessia
    Peducci, Maria
    Padiglioni, Chiara
    D'Amore, Cataldo
    Pierguidi, Laura
    Tambasco, Nicola
    Rossi, Aroldo
    Calabresi, Paolo
    BIOLOGICAL PSYCHIATRY, 2008, 64 (10) : 850 - 855
  • [45] Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies
    Stuendl, Anne
    Kunadt, Marcel
    Kruse, Niels
    Bartels, Claudia
    Moebius, Wiebke
    Danzer, Karin M.
    Mollenhauer, Brit
    Schneider, Anja
    BRAIN, 2016, 139 : 481 - 494
  • [46] Nicotinic receptors in the putamen of patients with dementia with Lewy bodies and Parkinson's disease:: relation to changes in α-synuclein expression
    Martin-Ruiz, C
    Lawrence, S
    Piggott, M
    Kuryatov, A
    Lindstrom, J
    Gotti, C
    Cookson, MR
    Perry, RH
    Jaros, E
    Perry, EK
    Court, JA
    NEUROSCIENCE LETTERS, 2002, 335 (02) : 134 - 138
  • [47] Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
    Burn, DJ
    McKeith, IG
    MOVEMENT DISORDERS, 2003, 18 : S72 - S79
  • [48] Cortical thinning in dementia with Lewy bodies and Parkinson disease dementia
    Colloby, Sean J.
    Watson, Rosie
    Blamire, Andrew M.
    O'Brien, John T.
    Taylor, John-Paul
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2020, 54 (06) : 633 - 643
  • [49] A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson's disease with dementia
    Fanciulli, Alessandra
    Leys, Fabian
    Lehner, Fabienne
    Sidoroff, Victoria
    Ruf, Viktoria C.
    Raccagni, Cecilia
    Mahlknecht, Philipp
    Kuipers, Demy J. S.
    van IJcken, Wilfred F. J.
    Stockner, Heike
    Musacchio, Thomas
    Volkmann, Jens
    Monoranu, Camelia Maria
    Stankovic, Iva
    Breedveld, Guido
    Ferraro, Federico
    Fevga, Christina
    Windl, Otto
    Herms, Jochen
    Kiechl, Stefan
    Poewe, Werner
    Seppi, Klaus
    Stefanova, Nadia
    Scholz, Sonja W.
    Bonifati, Vincenzo
    Wenning, Gregor K.
    BRAIN COMMUNICATIONS, 2022, 4 (04)
  • [50] Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies
    Aarsland, D
    Mosimann, UP
    McKeith, IG
    JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2004, 17 (03) : 164 - 171